Clearmind Medicine Inc., a clinical-stage pharmaceutical company, has filed its unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the three and six months ended April 30, 2024. The filings were made with the Canadian Securities Administration and the securities commissions of Ontario, British Columbia, and Alberta. The report, dated June 13, 2024, is incorporated by reference into the company's Registration Statements on Form F-3 with the SEC. Clearmind Medicine, trading under the symbol 'CMND' on the Nasdaq, focuses on developing psychedelic medicines for health issues such as Alcohol Use Disorder (AUD) and binge behaviors. The company has recently completed a Type A meeting with the FDA regarding its clinical trial for AUD treatment using its proprietary compound...Show More

Clearmind Medicine Inc., a clinical-stage pharmaceutical company, has filed its unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the three and six months ended April 30, 2024. The filings were made with the Canadian Securities Administration and the securities commissions of Ontario, British Columbia, and Alberta. The report, dated June 13, 2024, is incorporated by reference into the company's Registration Statements on Form F-3 with the SEC. Clearmind Medicine, trading under the symbol 'CMND' on the Nasdaq, focuses on developing psychedelic medicines for health issues such as Alcohol Use Disorder (AUD) and binge behaviors. The company has recently completed a Type A meeting with the FDA regarding its clinical trial for AUD treatment using its proprietary compound CMND-100. Additionally, Clearmind announced a series of patent applications and licensing agreements, including an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem for novel compounds to treat PTSD and other mental health conditions. The company also reported a net loss of $908,217 for the three months ended April 30, 2024, and a net loss of $2,276,017 for the six months ended on the same date. As of April 30, 2024, Clearmind had cash on hand of $8,305,927 and working capital of $4,491,100.